X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Eisai divested its rights for vertigo and equilibrium disturbance treatment Merislon (betahistine mesilate), used to treat Meniere's syndrome, and muscle relaxant Myonal (eperisone hydrochloride) in Japan to Kaken.
Lead Product(s): Betahistine Dimesilate
Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: Merislon
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Eisai
Deal Size: $25.0 million Upfront Cash: Undisclosed
Deal Type: Divestment March 29, 2024
Details:
NM26-2198 is a bi-specific antibody which targets IL-4Rα (type I and type II receptors) and IL-31 for the treatment of moderate-to-severe atopic dermatitis (AD).
Lead Product(s): NM26-2198
Therapeutic Area: Dermatology Product Name: NM26-2198
Highest Development Status: Phase IProduct Type: Large molecule
Recipient: Numab Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 15, 2023
Details:
Under the agreement, the companies will utilize the microbial platform technology developed by bitBiome to obtain drug candidates for the treatment of infectious diseases with high unmet medical needs.
Lead Product(s): Undisclosed
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Undisclosed
Recipient: bitBiome
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement March 29, 2023
Details:
Under the terms of the agreement, Kaken receives an exclusive license to develop, commercialize and market MBX-8025 (seladelpar), a first-in-class treatment for people with primary biliary cholangitis (PBC), in Japan for PBC.
Lead Product(s): Seladelpar
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: MBX-8025
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: CymaBay Therapeutics
Deal Size: $162.4 million Upfront Cash: $34.0 million
Deal Type: Collaboration January 08, 2023
Details:
SPR001 (tildacerfont) is a potent and highly selective, non-steroidal, oral antagonist of the corticotropin-releasing factor (CRF) 1 receptor. The CRF1 receptor is abundantly expressed in the pituitary gland where it is the primary regulator of the HPA axis.
Lead Product(s): Tildacerfont
Therapeutic Area: Genetic Disease Product Name: SPR001
Highest Development Status: Phase IIProduct Type: Small molecule
Recipient: Spruce Biosciences
Deal Size: Undisclosed Upfront Cash: $15.0 million
Deal Type: Partnership January 05, 2023
Details:
Under the expanded agreement, Kaken receives commercial rights for NM26-2198 in Japan, China, South Korea, Taiwan, Singapore, and Hong Kong, while Numab retains the commercial rights to the US, Europe, and the rest of the world.
Lead Product(s): NM26-2198
Therapeutic Area: Dermatology Product Name: NM26-2198
Highest Development Status: IND EnablingProduct Type: Large molecule
Recipient: Numab Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement January 13, 2021
Details:
Sofpironium bromide gel was deemed to be safe and well tolerated in this study, as well as in the accompanying 52-week long-term safety extension study in Japan. Japan is the first country to approve sofpironium bromide with commercial launch expected later this year.
Lead Product(s): Sofpironium Bromide
Therapeutic Area: Dermatology Product Name: Ecclock
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Fresh Tracks Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 25, 2020
Details:
Brickell and Kaken Pharmaceutical were granted by the Japanese Patent Office a composition of matter patent with claims directed to the novel polymorphic, or crystalline, forms of sofpironium bromide, a retrometabolically designed new chemical entity.
Lead Product(s): Sofpironium Bromide
Therapeutic Area: Dermatology Product Name: BBI-4000
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: Fresh Tracks Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 31, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
